Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
$1.62
-$0.03(-2.93%)
At close: 4:00 PM EST
$1.62
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.24 - $2.01
Previous CloseN/A
Volume22.63K
Average Volume (3M)1.52M
Market Cap
$99.70M
Enterprise Value$80.61M
Total Cash (Recent Filing)$25.60M
Total Debt (Recent Filing)$13.76M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Mar 16, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding71,212,360
10 Day Avg. Volume1,191,591
30 Day Avg. Volume1,521,247
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.97
Price to Sales (P/S)116.97
P/FCF Ratio-1.18
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue12.19
Enterprise Value/Gross Profit12.23
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$4.43Price Target Upside173.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPositive efficacy data from its OV329 Phase I program suggests potent GABA-AT inhibitory activity and clinical and preclinical data thus far assuage fear of retinal accumulation at relevant exposures from initial GABA-AT inhibitors.
Financial OutlookUpdating model and raising target to $5. We are incorporating the proceeds from the concurrent PIPE which totals ~$175M and extends cash runway into 2028.
LeadershipThe transition of new leadership is expected to be smooth with no negative impact on the probability of success for the company’s pipeline.
Bears Say
Efficacy ConcernsSubpar efficacy for OV329 could result in a lack of interest from key opinion leaders.
Safety ConcernsKey risks to the investment thesis include unexpected new safety signals, especially retinal toxicity for OV329.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $99.70M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 95 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 71,212,360 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.43 (173.46% Upside)
$4.43 (173.46% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.07%
12-Months-Change
Fundamentals
Return on Equity
-60.06%
Trailing 12-Months
Asset Growth
-37.80%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Stock 12 Month Forecast
Average Price Target
$4.43
▲(173.46% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
5.36% Insiders
4.86% Mutual Funds
25.82% Other Institutional Investors
60.45% Public Companies and Individual Investors